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ABSTRACT 
Background: Experimentally-induced total sleep deprivation (TSD) and chronic partial sleep 
restriction (CPSR) leads to the emergence of cognitive impairments. This is hypothesized to 
result from a consequent neuroinflammation which may also hasten the neurodegenerative 
processes. Neuroinflammatory markers such as tumor necrosis factor-alpha (TNFα) are 
thought to be potential culprits in SD-induced neurodegeneration. Methods: The effect of 
TSD and CPSR on memory and anxiety-related behaviors (using the Elevated Plus-Maze test-
retest protocol) and serum level of brain derived neurotrophic factor (BDNF) and corti-
costerone were assessed in male Wistar rats subjected to the modified disk-over-water (DOW) 
apparatus. In addition, an immunohistochemical (IHC) study was done to possibly detect the 
amyloid-beta (Aβ) and hyper-phosphorylated tau protein (HPτ) deposition in the dentate gy-
rus (DG) of the examined rats’ hippocampi. Histomorphology and neuronal numerical density 
assessments were done at the same level across control and experimental animals. We also 
studied the above parameters in rats after intraperitoneal injection of the TNFα neutralizing 
antibody, infliximab (IFX). Results: Rats subjected to TSD and CPSR which did not receive 
IFX, showed a more pronounced impairment of memory, elevated serum corticosterone and 
decreased BDNF levels. CPSR rats which underwent delayed brain excision following behav-
ioral testing, showed deposition of the HPτ and revealed the least numerical density in the 
hippocampal DG neurons. Meanwhile, IHC study revealed no Aβ deposition in the hippo-
campal DG of all examined rats. Interestingly, treatment with IFX, abrogated sleep re-
striction-induced cognitive decline, biochemical changes and the immunohistopathology in 
the hippocampal DG. Conclusions: Taken together, our findings indicated that CPSR (the SD 
model mimicking shift work) induces not only cognitive and biochemical changes, but also 
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pathology in the hippocampal DG. This is possibly via activation of the inflammatory mecha-
nisms in part through TNFα-dependent pathways. 
 
Keywords: Sleep deprivation, elevated plus-maze, corticosterone, BDNF, immunohistochem-
istry, infliximab, dentate gyrus, rat(s) 
 
 
 
INTRODUCTION 
One of the crucial functions of sleep is 
to promote synaptic plasticity and neuronal 
recovery which leads to a proper brain 
function (Benington, 2003; Tononi and 
Cirelli, 2006; Meerlo et al., 2009). While 
behavioral studies have endorsed the above 
notion, the precise cellular and molecular 
processes governing this fundamental func-
tion of sleep are yet to be fully understood.  
Based on the evidence from earlier ex-
periments, sleep deprivation (SD) attenu-
ates different markers of adult neurogenesis 
(Meerlo et al., 2009). Given this, and taking 
other changes into account, sleep loss is not 
only thought to leave detrimental effects on 
brain functionality but to speed up the pro-
gress of neuropathology.  
When sleep restriction becomes a 
chronic problem, it seems to even more 
deleteriously affect the brain. This is clini-
cally relevant since today’s competitive life 
with its shift work, around-the-clock style 
and the overall pressures, predisposes many 
people to have either restricted or disrupted 
sleep (Bonnet and Arand, 1995; Pilcher et 
al., 2000; Rajaratnam and Arendt, 2001). 
It has been noted that restricted sleep af-
fects various physiological parameters in-
cluding but not limited to the metabolic 
hormones and neuroinflammatory markers 
(Banks and Dinges, 2007). Therefore, SD is 
hypothesized to hasten neuroinflammation 
and subsequently the neurodegenerative 
processes (Livingston et al., 1993; Chang et 
al., 1997; Malow, 2004; Buysse et al., 
2008; Germain et al., 2008; Roane and 
Taylor, 2008). 
However, despite several studies devot-
ed to understanding the possible relation 
between sleep loss and neurodegeneration, 
no clear picture has yet emerged. It seems 
difficult to draw a conclusive image from 
the available SD-neurodegeneration evi-
dence, firstly because the earlier studies 
have employed various methods to induce 
SD, such as disk-over-water (DOW), tread 
mills, and multiple platforms each dealing 
with specific confounding variables. Sec-
ondly, each of the earlier studies has inves-
tigated a different sleep stage loss i.e. total- 
(TSD) or REM sleep deprivation (RSD) 
and few have modeled animals as shift-
work, and thirdly, a plethora of cellular and 
molecular methods have been used to look 
for neurodegeneration. Some methods only 
declare the neuronal damage during DNA 
degeneration (within a period of hours), 
while others such as amino cupric silver 
staining need two days to show something, 
if any. Therefore, many of these methods 
are not suitable to provide evidence for the 
slowly cumulating neurodegeneration over 
time. This slowly progressive neurodegen-
eration is hypothesized to be one of the 
consequences of the chronic partial sleep 
restriction (CPSR), which is an issue in to-
day’s life. 
SD-related neurodegeneration is 
thought to occur through at least two possi-
ble mechanisms: 1- altered level/effect of 
the neuroprotective markers and the result-
ant dominance in neuroinflammatory pro-
cesses and 2- the heightened sensitivity to 
neuronal excitatory pathways. Some earlier 
studies have indicated an enhanced expres-
sion of hippocampal glutamate receptors 
and Ca2+-induced excitotoxicity following 
SD (Ankarcrona et al., 1995; Sattler and 
Tymianski, 2000; Vyazovskiy et al., 2008). 
Moreover, SD has led to a various lev-
els of expression for neuroprotective factors 
such as nerve growth factor (NGF), brain 
derived neurotrophic factor (BDNF) and the 
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cAMP response element-binding protein 
(CREB) (Kume et al., 2000; Sei et al., 
2000; Guzman-Marin et al., 2006; Valera et 
al., 2008; Kim et al., 2009; Alhaider et al., 
2011). 
In the current study, we used an estab-
lished rat model of TSD and CPSR which 
partly mimics sleep loss in humans (Meerlo 
et al., 2002; Roman et al., 2005a, b). 
Knowing from the available data that 
sleep loss may influence neurogenesis, neu-
ronal plasticity and typical neurodegenera-
tive pathways, we hypothesized that SD in 
rats can increase the brain (especially hip-
pocampal) vulnerability to neurodegenera-
tion. Our hypotheses were: 1- SD influ-
ences memory function and anxiety level 
while antiinflammatory medications [here, 
the intraperitoneal (i.p.) injection of the an-
ti-TNFα monoclonal antibody, Infliximab 
(IFX)] may rescind these effects; 2- SD 
leads to increased deposition of beta-
amyloid peptide (Aβ) and hyper-
phosphorylated tau protein (HPτ) in the 
granular cell layer (GCL) of the hippocam-
pal dentate gyrus (DG) and IFX can affect 
this possible deposition (an immunohisto-
chemical assessment) and 3- SD leads to 
the altered serum level of BDNF and corti-
costerone and the i.p. IFX can possibly re-
store these changes. 
To test the above hypotheses, we em-
ployed a setup consisting of the DOW ap-
paratus to model the rats as TSD and CPSR, 
Enzyme-Linked Immuno-Sorbent Assay 
(ELISA) to assess the serum level of BDNF 
and corticosterone in the study arms and an 
immunohistochemical (IHC) method to ex-
amine the possible deposition of Aβ and 
HPτ in the GCL of the hippocampal DG. 
 
MATERIALS AND METHODS 
Animals 
Male albino Wistar rats weighing 220-
270 g, bred in the animal house of the Insti-
tute for Cognitive Science Studies (ICSS), 
Tehran, Iran, were used as subjects. Rats 
were housed in groups of four in Plexiglas 
home cages (45×30×15 cm) during which 
they had free access to food and water. An-
imals were kept under a light/dark cycle of 
12 h (lights on at 07:00 AM), with the tem-
perature ranging from 23±2 °C and the hu-
midity of 55-60 %. Animal handling was 
limited to the time of cage cleaning (every 
other day), weighing and drug administra-
tion. Each study arm consisted of eight an-
imals. Rats were handled about 3 min each 
day prior to the behavioral testing.  
 
Apparatus 
We used a carousel like device as a ro-
tating disk-over-water, known as the DOW 
apparatus (Everson et al., 1989; Recht-
schaffen et al., 1989; Rechtschaffen and 
Bergmann, 1995). This apparatus was used 
to induce TSD and CPSR in experimental 
rats. The apparatus housed two rats in sepa-
rate Plexiglas cages which shared a round 
disk as a partially elevated floor. Instead of 
the yolk controls, we used DOW controls 
(i.e. animals were placed in off apparatus 
for the given period of time). Beneath the 
disk floor were 6 cm deep trays filled with 
shallow water. The water temperature 
maintained at 29±2 ºC throughout the ex-
periments. This relatively higher than nor-
mal temperature was to let animals adjust 
with the well-defined thermoregulatory and 
metabolic syndrome possibly imposed by 
sleep deprivation procedure (Rechtschaffen 
and Bergmann, 1995). In the DOW method, 
when the rotating plate spins at a slow rate 
(4 rounds per minute), rats should keep 
pace when moving on the plate to avoid be-
ing sunk in the shallow water. Based on the 
earlier reports, the validated DOW setup 
(Everson et al., 1989; Rechtschaffen et al., 
1989; Rechtschaffen and Bergmann, 1995) 
causes the experimental rats to be effective-
ly (at least 85 % to 90 %) deprived from 
their sleep.  
Using the DOW apparatus housing two 
experimental rats for TSD or CPSR models, 
close observation (randomly 10 to 20 
blocks, each for 10 min, every day) as well 
as camera surveillance was done to ensure 
they actively and safely move around on the 
spinning plate or in water. The DOW con-
trol rats were housed in the off apparatus. 
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When in the apparatus, food (the standard 
lab oratory chow) and water were provided 
ad libitum and rats were closely monitored 
for their physical wellbeing and tolerance. 
Lighting schedule of the environment 
where the apparatus located was compliant 
with the standard L/D cycle, similar to the 
control condition. 
 
Behavioral testing using the Elevated 
Plus-Maze (EPM) apparatus 
Our EPM was made of black Plexiglas 
(floor and walls) and set elevated to the 
floor at a 50 cm height. It composed of two 
50×10 cm open arms and two 
50×10×40 cm enclosed arms, each with an 
open roof. The junction area of the four 
arms (the central platform) measured 
10×10 cm. The maze was placed at the cen-
ter of a quiet and dimly lit room (Zarrindast 
et al., 2010, 2011). All EPM experiments 
on rats were carried out between 14:00 h 
and 17:00 h. 
We used the test-retest EPM protocol 
through which anxiety level (on test day) 
and the aversive memory retrieval (on retest 
day, 24 h later) could be evaluated. Rats 
who were assigned to any control or exper-
imental arms were placed in the experi-
mental room at least 1 h before testing. 
They were then individually placed at the 
center of the plus-maze, facing one of the 
open arms and allowed for 5 min free ex-
ploration in the EPM (the test session) after 
which were taken back to their home cages. 
In 24 hours, rats were returned to the test 
room and placed again in the EPM for a 
new exploration period of 5 min (the retest 
session). Animals’ behaviors were tracked 
and recorded by an observer who quietly sat 
1 m behind one of the closed arms of the 
maze, using a chronometer. The observer 
measured:  
1- the time spent in open arms, 
2- the time spent in closed arms,  
3- the number of entries into open arms and 
4- the number of entries into closed arms 
during the five minute period both upon test 
and retest. An entry was defined as “all four 
paws in the arm”. In between the EPM tests 
and after each rat, the maze was cleaned 
with distilled water. The obtained data were 
used to calculate:  
a- % OAT (the ratio of time spent in open 
arms to the time spent in all arms ×100);  
b- %OAE (the ratio of entries into open 
arms to total entries×100) and  
c- the total closed and open arm entries (a 
relatively pure index for the locomotor ac-
tivity) (Zarrindast et al., 2010; Eslimi et al., 
2011). The number of rearings (rats main-
taining an erect posture), groomings (rats 
rubbing their face including ears, mouth, 
vibrissae, eyes with rapid circular move-
ments of their forepaws) and defecations 
(the number of passed fecal boli) were 
manually recorded as the conventional indi-
ces for anxiety-related behaviors 
(Zarrindast et al., 2010, 2011; Eslimi et al., 
2011).  
 
Study design 
Rats were assigned to different study 
arms based on: 1- whether they had no SD 
[cage control (CC) vs. DOW apparatus con-
trol (DOW-C)] or sleep-deprived (TSD for 
48 hours vs. CPSR i.e. intermittently sleep-
deprived for 7 consecutive days) and 2- 
whether they had received i.p. IFX (the 
TNFα neutralizing antibody) vs. PBO (Pla-
cebo/saline) 15 minutes prior to the inter-
ventions. Following the procedure and be-
havioral testing in different arms, blood 
sampling was done and the rats were eu-
thanized with their brain removed for neu-
rohistopathological studies. The sub-
analysis was based on “when” the blood 
was drawn and brains were excised [i.e. 
immediately after the completion of behav-
ioral testing (early brain excision/EBE) vs. 
two weeks later (late brain excision/LBE)]. 
For the study arms, we had two sets of 
stratifications leading to 12 arms. The first 
set of stratifications comprised:  
arm 1- PBO/CC/48 h;  
arm 2- PBO/DOW-C/48 h;  
arm 3- PBO/CC/7 days;  
arm 4- PBO/DOW-C/7 days;  
arm 5- PBO/TSD/48 h and  
arm 6- PBO/CPSR/7 days.  
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The second set of stratifications consist-
ed of:  
arm 1- IFX/CC/48 h;  
arm 2- IFX/DOW-C/48 h;  
arm 3- IFX/CC/7 days;  
arm 4- IFX/DOW-C/7 days;  
arm 5- IFX/TSD/48 h and  
arm 6- IFX/CPSR/7 days.  
For TSD, the DOW apparatus was con-
tinuously rotating for 48 h and for CPSR, 
an automatically set timer allowed the ap-
paratus to be 12 h on (08:00 h to 20:00 h) 
and 12 h off (20:00 h to 08:00 h), intermit-
tently for 7 consecutive days. The study de-
sign has been illustrated in Figure 1. 
 
 
 
 
 
 
 
Figure 1: Study design diagram 
The variables through which stratification into these arms was made were: 
1- sleep deprived (either TSD or CPSR) vs. control (either CC or DOW-C);  
2- the length of intervention or control condition (i.e. 48 h vs. 7 days);  
3- PBO vs. IFX treatment and  
4- early (immediately after EPM retest) vs. late (14 days after EPM retest) blood sampling for serum 
neurochemical assessment or early vs. late brain excision for IHC/histomorphological study of the hip-
pocampus. By this, two sets of stratification (each comprising six arms) were defined. The 12 study 
arms with their assignment criteria are depicted in this diagram. TSD: total sleep deprivation, CPSR: 
chronic partial sleep restriction, CC: cage control, DOW-C: disk-over-water apparatus control, PBO: 
placebo, BS: blood sampling, IFX: infliximab, EPM: elevated plus-maze, IHC: immunohistochemistry 
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Drugs 
Infliximab (Schering Plough, NJ, USA), 
the chimeric human-murine anti-tumor ne-
crosis factor-alpha (TNFα) monoclonal an-
tibody or PBO (saline) were injected i.p. to 
all control (CC and DOW-C) and experi-
mental (TSD and CPSR) rats 15 minute be-
fore submitting them to the SD procedures 
(TSD or CPSR) or control conditions (cage 
or off apparatus) (Figure 1). The TNFα- 
neutralizing Ab, infliximab (IFX), binds 
with high affinity and avidity to the soluble, 
transmembrane and receptor-bound forms 
of TNFα but not to lymphotoxin α (TNFβ). 
Infliximab neutralizes the TNFα heterotri-
mers and inhibits their inflammatory effect 
on target cells. Since TNFα is considered a 
death ligand and contributes to apoptotic 
pathways following the oxidative stress 
(Figure 2), IFX was expected to lessen the 
adverse effects of SD both behaviorally and 
histopathologically. That was the reason 
IFX was applied in the current investiga-
tion. IFX is a commercially available medi-
cation used for distinct immune-mediated 
inflammatory disorders (IMIDs) in clinical 
medicine at 3-5 mg/kg based on the indica-
tions such as rheumatoid arthritis, ankylos-
ing spondylitis, psoriasis, ulcerative colitis 
and Crohn's disease (Infliximab summary 
of product characteristics, Schering Plough, 
2010). As described in an earlier investiga-
tion (Karson et al., 2013), and based on our 
observations, since 4 mg/kg of i.p. IFX ren-
dered no effect on anxiety-related behaviors 
or memory functions in rats by itself, this 
dose was used as the subthreshold applied 
dose in our experiments.  
 
Figure 2: Extrinsic pathway of the apoptotic 
caspase cascade  
This pathway is initiated through binding of 
death ligands such as TNFα to their receptors. 
This in turn would activate membrane-proximal 
caspases (caspase-9 and 10) and eventually 
induces the activation of caspase-3 and thereby 
promotes cell death. The oxidative stress is 
thought to contribute to this mechanism, in 
which TNFα seems to play an active part. The 
previously described neuronal cell death in the 
hippocampal dentate gyrus following sleep dep-
rivation in rodents is thought to be at least partly 
resulted from TNFα. Therefore, anti TNFα 
monoclonal Ab, infliximab, was applied to inves-
tigate whether it prevents the neuroinflammato-
ry consequences of sleep loss. Adapted from 
(http://ptglab.com), Jan. 2013, with permission. 
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The serum neuro-biochemical, tissue  
immunohistochemical and stereological 
assessments 
Neuro-biochemical measurements 
According to the rats’ stratification into 
the study arms, either immediately after 
EPM retest session (early blood sampling) 
or 14 days later (late blood sampling), each 
animal was euthanized using inhaled chlo-
roform, after which 3 ml blood was ob-
tained transcardially and centrifuged (the 
above process was done between 17:00 h 
and 18:00 h). Serum was isolated and 
stored at -20 °C in EDTA tubes. Serum 
BDNF and corticosterone levels were 
measured using the sandwich ELISA (En-
zyme-Linked Immuno-Sorbent Assay) 
method. The monoclonal Anti-BDNF anti-
body 1B10 (Sigma-Aldrich Inc.) and Rat 
Corticosterone ELISA Kit, 96T (BIOTANG 
Inc.) were used in our biochemical assess-
ments.  
Brain collection 
Either immediately after the EPM retest 
session (early brain excision/EBE) or 14 
days later (late brain excision/LBE), ani-
mals were euthanized and their brains were 
removed from the skull, postfixated in 4 % 
paraformaldehyde for 24 h and immersed in 
30 % sucrose for an additional 48 h for cry-
oprotection.  
The brains were collected for immuno-
histochemical and further histological 
(Mouton et al., 2002) and stereological 
study (Namavar et al., 2012).  
The immunohistochemical study for the de-
tection of Aβ peptide and HPτ protein in the 
hippocampal DG 
The formalin-fixed paraffin embedded 
brain blocks of all rats were sectioned and 
tissue slices at DG level of the hippocampi 
were mounted on slides (sections were 
mainly taken from -2.5 mm to -5.0 mm 
from bregma according to the atlas of rats’ 
brain) (Paxinos and Watson, 2007). Sec-
tions were pretreated for 30 min with 0.3 % 
H2O2 to prevent non-specific staining be-
fore incubation with 1:200 mouse anti-beta 
amyloid antibody (DE2B4-ab11132, 
Abcam, Cambridge, UK) or with anti-tau 
antibody (E178-ab32057, Abcam, Cam-
bridge, UK) for 24 h at 4 °C. When prepar-
ing negative control slides, this step was 
skipped. Tissues were then exposed to 
1:500 mouse and rabbit specific horseradish 
peroxidase/diaminobenzidine  (HRP/DAB) 
secondary antibody (ab64264, Abcam, 
Cambridge, UK) for 2 h. Sections were 
subsequently incubated for 1 h with 1:500 
Streptavidine-DAB chromogen complex 
(ab64264, Abcam, Cambridge, UK) and 
0.003 % H2O2. The whole immunohisto-
chemical (IHC) staining for Aβ peptide and 
HPτ protein were carried out according to 
previously published methods and the ma-
nufacturer’s manuals (Papasozomenos and 
Su, 1991; Li et al., 1995). Prepared slides 
were studied both by an IHC expert and an 
independent pathologist blinded to the 
study protocol to interpret the IHC study 
results of all preparations (control vs. sleep-
deprived rats who had either been PBO- or 
IFX-treated). 
Histomorphological assessments 
To assess the numerical density of the 
granular cell layer (GCL) neurons of the 
DG and further histomorphological evalua-
tions, processed brain tissues were coronal-
ly and serially sectioned, using a cryostat 
(SLEE, Frankfurt, Germany) at a thickness 
of 30 μm throughout the hippocampal DG, 
and were immersed in cryoprotectant solu-
tion and retained at -20 °C, till needed. Eve-
ry 6th section provided a mounted slide 
which was stained using cresyl violet.  
The numerical density assessment of the 
hippocampal DG neurons in sleep-deprived 
and control rats were done using the optical 
disector technique (Abusaad et al., 1999). 
This setup comprised an Eclipse micro-
scope (E200, Nikon, Tokyo, Japan) pos-
sessing a high numerical-aperture 
(NA=1.25)×60 oil-immersion objective. 
The setup was connected to a video camera, 
transmitting the image to the monitor. For 
motion correction, the device was equipped 
with an electronic microcenter digital 
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readout (MT12, Traunreut, Germany). The 
neuronal density was defined as follows: 
NV=∑Q/[∑P×a(f)×h]. In this calculation, 
∑Q is the number of neurons counted, ∑P 
is number of dissector, a(f)=0.001369 mm2, 
is the area of the sampling frame, and 
h=0.015 mm, is the height of the dissector 
(Gundersen et al., 1988, 1999; Abusaad et 
al., 1999; Namavar et al., 2012). To facili-
tate cell counting, we employed an auto-
mated image analysis system (Leica Qwin, 
Rijswijk, the Netherlands). Neuronal nuclei 
were counted in 3±1 sections using our set-
up at a 400x final magnification. Through 
the optical dissector technique (Mouton et 
al., 2002), result values were reported as the 
number of DG neurons per mm3.  
Ethical issues 
The specific ethical concern about the 
extent of sleep loss imposed by a device 
like DOW was dealt with according to the 
Guidelines for the care and use of mammals 
in neuroscience and behavioral research 
(2003). To refine DOW method and make it 
least cruel and invasive possible, guideline 
measures were meticulously observed. All 
efforts were made to minimize animal suf-
fering and to reduce the number of animals 
used. 
Based on this and referring to the local 
guidelines for animal care and use, the 
study was approved by the ethics commit-
tee of the Institute for Cognitive Science 
Studies.  
 
Experimental design 
Experiment 1: Open-arms exploratory be-
haviors of sleep-deprived and control ani-
mals submitted to EPM test-retest protocol, 
in the presence or absence of infliximab 
injection   
To examine the extent of TSD or CPSR 
involvement in the presence or absence of 
IFX injection in anxiety and memory func-
tion, IFX or PBO was injected to animals 
15 min before being submitted to the SD 
procedure. The control rats similarly re-
ceived either IFX or PBO. EPM testing was 
done following the interventions (see Fig-
ure 1). The animals’ open arms exploratory 
behaviors on test day corresponded to anxi-
ety while same indices during retest at-
tributed to the EPM-associated memory re-
trieval.  
Experiment 2: Assessing the possible effect 
of sleep loss on serum BDNF and corti-
costerone levels in the presence or absence 
of infliximab injection 
Following the EPM retest, based on the 
study arm to which rats were assigned, 
blood sampling was done in early or late 
setting as described in the method section. 
BDNF and corticosterone serum levels 
were measured using the ELISA method. 
The effect of sleep loss in presence or ab-
sence of IFX injection on these chemicals’ 
serum level was compared across groups.  
The immunohistochemical detection of Aβ 
and HPτ in the hippocampal DG of sleep-
deprived vs. control rats in the presence or 
absence of infliximab injection  
Whether animals’ brain were removed 
early or late (as described in methods), tis-
sues were submitted to the IHC study for 
possible detection of Aβ or HPτ protein in 
the DG of the hippocampi. In this experi-
ment, prepared tissue slides from the hippo-
campi of 12 groups of rats were examined. 
These experimental or control rats had al-
ready received either IFX or PBO. Qualita-
tive analysis was done to interpret the IHC 
study results. 
Histomorphological evaluations in the hip-
pocampal DG of sleep-deprived vs. control 
rats in the presence or absence of inflixi-
mab injection 
Brain tissues of the 12 study arm ani-
mals were sectioned and stained with cresyl 
violet. The numerical density of the DG 
neurons was measured to see whether TSD 
or CPSR in presence or absence of IFX in-
jection affect this variable.   
 
EXCLI Journal 2013;12:347-372 – ISSN 1611-2156 
Received: March 21, 2013, accepted: April 14, 2013, published: April 30, 2013 
 
355 
Statistical analyses 
Given the normality of distribution and 
homogeneity of variance, to analyze the 
obtained behavioral tests data (i.e. EPM 
measures such as %OAT, %OAE, locomo-
tion, rearing, grooming and defecation) dur-
ing test and retest sessions in the presence 
or absence of IFX injection, we employed 
the repeated measure analysis of variance 
(ANOVA). Moreover, two ANOVA was 
used to analyze the serum BDNF and corti-
costerone data. When ANOVA revealed 
any significance, post hoc Tukey’s test was 
used to assess differences between specific 
treatment arms. 
To establish if TSD and CPSR rats vs. 
their corresponding controls in the presence 
or absence of IFX injection, show evidence 
of Aβ and HPτ deposition in DG, the ob-
servations across groups were qualitatively 
compared using the Pearson’s chi-squared 
test. Additionally, to compare the neuronal 
numerical density/mm3 amongst groups, we 
used two-way ANOVA. Upon significance, 
post hoc Tukey’s test was applied to deter-
mine differences between specific groups. 
The level of significance for all tests was 
P<0.05. All data were expressed as mean ± 
S.E.M.  
 
RESULTS 
Experiment 1: Open-arms exploratory be-
haviors of sleep-deprived and control ani-
mals submitted to EPM test-retest protocol 
in the presence or absence of infliximab 
injection  
Repeated measure analysis of variance 
declared that TSD and CPSR increase 
%OAT (Figure 3A), %OAE (Figure 3, 2B) 
and the number of groomings (Figure 4B) 
while do not alter the locomotor activity 
(Figure 3C).  
SD (in the presence or absence of IFX 
injection) led to a notable decrease in the 
number of rearings and defecations on test 
and retest days as compared to controls 
(Figure 4A and C). Increased %OAT during 
the T1 EPM session indicates the anxiolyt-
ic-like response induced by TSD and CPSR 
(Figure 3A). However, this effect was more 
pronounced in CPSR as compared to TSD 
rats (p<0.01) (Figure 3, panel 1A). As com-
pared to PBO-treated rats, TSD animals 
which received IFX showed even more in-
crease in %OAT on test day which indicat-
ed a more pronounced anxiolytic-like effect 
of TSD in this group (Figure 3, panel 3A). 
Results indicated an increase in %OAT and 
%OAE upon retest (T2 session) in TSD and 
CPSR rats (Figure 3A and B). While the 
analysis for PBO-treated TSD and CPSR 
animals showed an increased %OAT in T2 
(which corresponds to EPM-associated 
memory impairment), IFX could partially 
revert this SD-induced memory impairment 
(Figure 3, panels 4A and 4B). Taken to-
gether, the increased %OAT and %OAE 
(during T2) could be interpreted as impair-
ment of memory consolidation and retrieval 
following TSD and CPSR which was par-
tially abrogated by IFX injection. The re-
sults of this experiment are illustrated in 
Figure 3 and 4. In addition, the quantitative 
statistical analysis outcome for this experi-
ment is summarized in Table 1. 
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Figure 3: EPM test-retest paradigm 
Open-arms exploratory behaviors following control condition or sleep deprivation (TSD or CPSR) upon 
PBO (panels 1 and 2) and IFX (panels 3 and 4) i.p. injection, 15 min before the intervention. %Open-
Arms Time (A); %Open-Arms Entries (B) and locomotion (C). Values are expressed as mean±S.E.M 
(n=8 in each group). *P<0.05, **P<0.01 and ***P<0.001 different from their corresponding control arms 
( i.e. CC or DOW-C) in each panel. For the TSD groups, the corresponding control arms are CC 48 h 
and DOW-C 48 h while for CPSR, the corresponding controls are CC-7 days and DOW-C 7 days. 
Panel 1. ++P<0.01 different from TSD in the same panel. Panel 3, ###P<0.001 different from the cor-
responding arm (TSD) in panel 1. Panel 4, +++P<0.001 different from TSD in the same panel. Panel 
4, $$$P<0.001 different from the corresponding arm (TSD) in panel 2. Panel 4, @P<0.05 different 
from the corresponding arm (CPSR) in panel 2. TSD: total sleep deprivation, CPSR: chronic partial 
sleep restriction, PBO: placebo, IFX: infliximab, CC: cage control, DOW-C: disk-over-water apparatus 
control 
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Figure 4: EPM test-retest paradigm 
Auxiliary open-arms exploratory behaviors [Rearing (A); grooming (B) and defecation (C)] following 
control condition or sleep deprivation (TSD or CPSR) upon PBO (panels 1 and 2) and IFX (panels 3 
and 4) i.p. injection, 15 min before the intervention. Values are expressed as mean±S.E.M (n=8 in 
each group). *P<0.05, **P<0.01 and ***P<0.001 different from their corresponding control arms (i.e. 
CC or DOW-C) in each panel. For the TSD groups, the corresponding control arms are CC 48 h and 
DOW-C 48 h while for CPSR, the corresponding controls are CC-7 days and DOW-C 7 days. Panel 1, 
+P<0.05 different from TSD in the same panel. Panel 3, ^P<0.05 different from the corresponding arm 
(CPSR) in panel 1. Panel 4, +P<0.001 different from TSD in the same panel and @P<0.05 different 
from the corresponding arm (CPSR) in panel 2. TSD: total sleep deprivation, CPSR: chronic partial 
sleep restriction, PBO: placebo, IFX: infliximab, CC: cage control, DOW-C: disk-over-water apparatus 
control 
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Table 1: Repeated measure analysis and two-way ANOVA results with P values for the effect of sleep 
deprivation vs. control condition 
These interventions were in the presence (panels 3 and 4 in Figure 3 and 4) or absence (panels 1 and 
2 in Figure 3 and 4) of anti TNFα (IFX) injection. The effect of such interventions on EPM indices (ex-
ploratory-like behaviors) including %OAT, %OAE, locomotion, rearing, grooming and defecation, have 
been demonstrated. IFX: infliximab, EPM: elevated plus-maze, %OAT: open arm time percentage, 
%OAE: open arm entries percentage 
 
 
 
Experiment 2: Assessing the possible effect 
of sleep loss on the serum BDNF and corti-
costerone levels in the presence or absence 
of infliximab injection 
In this experiment, we assessed the se-
rum BDNF and corticosterone levels fol-
lowing sleep deprivation or control condi-
tion in PBO- vs. IFX-treated animals. Rats 
were submitted to either early (immediately 
after EPM retest) or late (after 14 days) 
blood sampling to have their serum BDNF 
and corticosterone levels measured (ELI-
SA). While PBO-treated TSD and more 
significantly, CPSR rats, showed decreased 
level of BDNF and peaked corticosterone, 
treatment with IFX partially rescinded these 
changes when blood was drawn in early 
setting. On the other hand, in late blood 
sampling, IFX almost completely blocked 
the SD-induced changes in BDNF and cor-
ticosterone. This possibly indicates the cen-
tral role of TNFα in the inflammatory pro-
cesses leading to such neuro-biochemical 
changes following SD. The results of this 
experiment are demonstrated in Figure 5 
and 6. In addition, the quantitative statisti-
cal analysis outcome for this experiment is 
summarized in Table 2.  
 
 
Type of 
analysis 
 
EPM  
indices 
within-subjects 
effects 
between-subjects
effects tests × groups 
F (1, 42) P F (5, 42) P F (5, 42) P 
Repeated 
measure  
between  
panels 1 and 2 
%OAT 34.88 0.0005 155.00 0.0005 19.05 0.0005 
%OAE 8.27 0.01 18.00 0.0005 3.34 0.05 
Locomotion 43.41 0.0005 2.21 0.072 3.75 0.007 
Grooming 20.10 0.0005 22.31 0.0005 3.46 0.01 
Rearing 4.48 0.040 10.76 0.0005 1.262 0.30 
Defecations 5.61 0.023 12.94 0.0005 2.57 0.041 
Repeated 
measure 
between  
panels 3 and 4 
 F (1, 42) P F (5, 42) P F (5, 42) P 
%OAT 219.10 0.0005 60.80 0.0005 11.82 0.0005 
%OAE 45.64 0.0005 25.25 0.0005 1.97 0.10 
Locomotion 18.17 0.0005 1.06 0.40 4.91 0.001 
Grooming 3.90 0.005 14.11 0.0005 1.11 0.30 
Rearing 21.61 0.0005 89.48 0.0005 2.66 0.035 
Defecations 3.10 0.09 12.77 0.0005 0.76 0.58 
Two-Way 
ANOVA  
between  
panels 1 and 3 
 F (1, 84) P F (5, 84) P F (5, 84) P 
%OAT 16.86 0.0005 42.18 0.0005 8.06 0.0005 
%OAE 24.37 0.0005 19.77 0.0005 2.00 0.088 
Locomotion 19.79 0.0005 4.19 0.002 0.838 0.53 
Grooming 1.19 0.277 38.82 0.0005 1.09 0.28 
Rearing 8.97 0.004 34.80 0.0005 3.11 0.013 
Defecations 7.47 0.008 8.20 0.0005 1.21 0.311 
Two-Way 
ANOVA  
between  
panels 2 and 4 
 F (1, 84) P F (5, 84) P F (5, 84) P 
%OAT 59.95 0.0005 195.5 0.0005 10.12 0.0005 
%OAE 7.89 0.006 37.56 0.0005 1.51 0.19 
Locomotion 46.06 0.0005 5.137 0.0005 1.058 0.39 
Grooming 2.63 0.11 12.66 0.0005 1.33 0.258 
Rearing 1.78 0.186 27.38 0.0005 3.4 0.008 
Defecations 4.38 0.04 15.18 0.0005 2.7 0.026 
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Figure 5: Serum BDNF levels following sleep deprivation or control condition in PBO- vs. IFX-treated 
animals 
Rats were submitted to either early (immediately after the EPM retest) or late (after 14 days) blood 
sampling to have their serum BDNF level assessed (ELISA). Values are expressed as mean±S.E.M 
(n=8 in each group), pg/ml. **P<0.01 and ***P<0.001 different from corresponding control arms in the 
same panel. For the TSD groups, the corresponding control arms are CC 48 h and DOW-C 48 h while 
for CPSR, the corresponding controls are CC-7 days and DOW-C 7 days. Panel A and C, ++P<0.01 
and +++P<0.001 different from TSD arm in the same panel. Panel B, ###P<0.001 different from the 
respective arm (TSD) in panel A. Panel B, $$$P<0.001 different from the respective arm (CPSR) in 
panel A. Panel D, &&&P<0.001 different from the respective arm (TSD) in panel C. Panel D, 
^^^P<0.001 different from respective arm (CPSR) in panel C. BDNF: brain derived neurotrophic factor, 
EPM: elevated plus-maze, ELISA: enzyme-linked immunosorbent assay, pg/ml: picogram per milliliter, 
TSD: total sleep deprivation, CPSR: chronic partial sleep restriction, PBO: placebo, IFX: infliximab, 
CC: cage control, DOW-C: disk-over-water apparatus control 
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Figure 6: Serum corticosterone levels following sleep deprivation or control condition in PBO- vs. IFX- 
treated animals 
Rats were submitted to either early (immediately after the EPM retest) or late (after 14 days) blood 
sampling to have their serum corticosterone level assessed (ELISA). Values are expressed as 
mean±S.E.M (n=8 in each group), mcg/dl. *P<0.05 and ***P<0.001 different from corresponding con-
trol arms in the same panel. For the TSD groups, the corresponding control arms are CC 48 h and 
DOW-C 48 h while for CPSR, the corresponding controls are CC-7 days and DOW-C 7 days. Panel A, 
B and C, +++P<0.001 different from TSD arm at the same panel. Panel B, $P<0.05 different from the 
respective arm (CPSR) in panel A. Panel D, ^^^P<0.001 different from the respective arm (CPSR) in 
panel C. Panel D, @@@P<0.001 different from the respective arm (CPSR) in panel B. EPM: elevated 
plus-maze, ELISA: enzyme-linked immunosorbent assay, mcg/dl: microgram per deciliter, TSD: total 
sleep deprivation, CPSR: chronic partial sleep restriction, PBO: placebo, IFX: infliximab, CC: cage 
control, DOW-C: disk-over-water apparatus control 
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Table 2: Two-way ANOVA results with P values for the effect of sleep deprivation interventions vs. 
control condition 
Type of 
analysis 
Specimen 
collection 
within-subjects  
effects 
between-subjects 
effects tests × groups 
F (1, 84) P F (5, 84) P F (5, 84) P 
Two-Way 
ANOVA for 
BDNF 
for early brain 
excision 47.5 0.0005 27.37 0.0005 8.18 0.0005 
for late brain 
excision 61.88 0.0005 12.26 0.0005 10.77 0.0005 
Two-Way 
ANOVA for 
Corticosterone 
for early brain 
excision 14.3 0.0005 46.94 0.0005 2.76 0.02 
for late brain 
excision 5.32 0.024 13.43 0.0005 3.84 0.003 
Two-Way 
ANOVA for 
neuronal  
numerical 
density in  
dentate gyrus 
for early brain 
excision 6.96 0.01 24.99 0.0005 1.024 0.41 
for late brain 
excision 3.72 0.07 31.10 0.0005 1.77 0.43 
These interventions were in the presence or absence of anti TNFα (IFX) injection (panels A-D in Fig-
ure 5, 6 and 7), upon early (immediately after EPM retest) vs. late (14 days after EPM retest) blood 
sampling or early vs. late brain excision. The effect of such interventions on serum levels of 
BDNF/corticosterone and the numerical density of the hippocampal dentate gyrus neurons, have been 
demonstrated. IFX: infliximab, EPM: elevated plus-maze, BDNF: brain derived neurotrophic factor  
 
The immunohistochemical detection of Aβ 
and HPτ in the hippocampal DG of sleep-
deprived vs. control rats in the presence or 
absence of infliximab injection  
The IHC study of the hippocampal DG 
of all examined rats (sleep deprived vs. 
control, PBO-treated vs. IFX-treated, early 
brain excision vs. late brain excision) re-
vealed no evidence of Aβ deposition. How-
ever, in the absence of any tissue reaction in 
negative controls for HPτ, CPSR rats which 
received PBO and underwent late brain ex-
cision showed positive staining reaction for 
HPτ. Interestingly, IFX (4 mg/kg i.p. injec-
tion) prevented this reaction suggesting the 
possible role of TNFα as a pivotal proin-
flammatory mediator in the above process. 
In summary, while Aβ deposition did not 
occur across groups, unlike all other arms, a 
significant positive staining reaction with 
regard to HPτ, in PBO-CPSR-LBE group 
was noted (r2=0.8). The IHC findings in the 
hippocampal DG are demonstrated in Fig-
ure 7. 
Histomorphological evaluations in the hip-
pocampal DG region of sleep-deprived vs. 
control rats in the presence or absence of 
infliximab injection 
Nissl staining of the rats’ hippocampal 
sections at the level of DG showed the 
presence of dark neurons, comparatively 
more in PBO-CPSR-LBE group animals. 
Measuring the numerical density (i.e. the 
number of neurons/mm3) indicated that the 
number of DG neurons declined following 
SD. This decline was more pronounced in 
CPSR rats with late brain excision (with the 
least number of neurons/mm3), however the 
difference was not statistically significant 
as compared to other CPSR groups. Inter-
estingly, both in TSD and CPSR arms, IFX 
injection (4 mg/kg, i.p.) resulted in preven-
tion of the numerical density decline in DG. 
This suggests the possible role of IFX to at 
least partly hamper the apoptotic pathways 
leading to the neuronal cell death in DG 
following an oxidative stress such as SD. 
The results of this experiment are summa-
rized in Figure 8. In addition, the quantita-
tive outcome of the statistical analysis on 
this experiment is outlined in Table 2. 
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Figure 7: IHC study of the prepared tissue slides for the detection of Aβ and HPτ protein in the hippocam-
pal DG in all examined groups ( n=8/arm and n=4/group, see Figure 2, the study design) 
Presence of antigen produces brown discoloration when encounters specific monoclonal antibodies 
(DE2B4- ab11132 for Aβ and E178-ab32057 for HPτ) in this method. Comparable to negative control slides 
(in which the application of primary antibody was skipped during the IHC protocol), no tissue staining reac-
tion for Aβ was found in all slides examined (controls vs. sleep-deprived groups, on PBO vs. IFX). Mean-
while in the absence of any tissue reaction in negative controls for HPτ, CPSR rats which received PBO and 
underwent LBE showed positive staining reaction for HPτ (H, L: arrows). This may be a good sign of τ de-
position following sleep loss in long run. Interestingly, IFX (4 mg/kg i.p. injection) prevented this reaction 
suggesting the possible role of TNFα in the above process. While Aβ deposition did not occur across 
groups, unlike all other arms, a significant positive staining reaction with regard to HPτ, in PBO-CPSR-LBE 
group was noted. IHC: immunohistochemical, DG: dentate gyrus, Aβ: amyloid beta peptide, HPτ: hyper-
phosphorylated tau protein, IFX: infliximab, PBO: placebo, CPSR: chronic partial sleep restriction, i.p.: in-
traperitoneally 
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Figure 8: Nissl stain-
ing of rats’ hippo-
campal sections at 
the level of DG. A-H 
images represent the 
hippocampal DG sec-
tions of the rats as-
signed to each arm 
(control vs. sleep-
deprived) which had 
been either PBO- or 
IFX-treated with early 
(immediately after 
EPM retest) or late 
(after 14 days) brain 
excision. (A) cage 
control for 48 h or 7 
days on either BPO 
or IFX; (B) DOW-
control for 48 h or 7 
days on either PBO 
or IFX; (C) TSD on 
PBO with late brain 
excision (LBE); (D) 
TSD on IFX with 
LBE; (E) CPSR on 
PBO with LBE; (F) 
CPSR on IFX with 
LBE; (G) CPSR on 
PBO with early brain 
excision (EBE); (H) 
CPSR on IFX with 
EBE. The graph be-
neath, represents the 
mean ± S.E.M for the 
numerical density 
(i.e. the number of 
neurons/mm3) calcu-
lated as described in 
methods section. 
**P<0.01 and 
***P<0.00, different 
from the correspond-
ing control arms in 
the same panel. For 
the TSD groups, the 
corresponding control 
arms are CC 48 h 
and DOW-C 48 h 
while for CPSR, the 
corresponding con-
trols are CC-7 days and DOW-C 7 days. Panels A-D, +P<0.05 and ++P<0.01, different from TSD arm in 
each panel. Panel B, #P<0.05 different from the corresponding arm (TSD) in panel C.  As shown in the up-
per figure, PBO-CPSR-LBE group (E) was the most vulnerable group with 6±2 dark neurons per a high 
power field (HPF) (arrows point at presumably apoptotic neurons) and wider inter-cellular spaces. Likewise, 
as per numerical density data for DG neuron/mm3, PBO-CPSR-LBE rats demonstrated the least value 
(13710 ± 391 neurons/mm3), however not significantly different from the CPSR arms (i.e. panels A, C and 
D). Interestingly, both in TSD and CPSR arms, IFX injection resulted in prevention of numerical density de-
cline in DG. DG: dentate gyrus, GCL: granular cell layer, EBE: early brain excision, LBE: late brain excision, 
TSD: total sleep deprivation, CPSR: chronic partial sleep restriction, PBO: placebo, IFX: infliximab, CC: 
cage control, DOW-C: disk-over-water apparatus control. PBO: placebo, IFX: infliximab 
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DISCUSSION 
This study which evaluated the conse-
quences of sleep loss (TSD and CPSR) on 
EPM-associated memory and anxiety-
related behaviors in a rat model, also as-
sessed the serum neurochemical changes 
and hippocampal DG histopathological out-
comes, in the presence or absence of i.p. 
IFX. We showed that PBO-treated CPSR 
rats had a more drastically impaired aver-
sive memory function as well as more pro-
nounced anxiolytic-like behaviors. More-
over, in the absence of Aβ deposition in the 
hippocampal DG of all examined rats, we 
observed a positive IHC reaction for HPτ in 
the DG of PBO-treated CPSR rats with late 
brain excision. Our results also showed that 
IFX abrogates this reaction. Likewise, the 
above group in which brains were removed 
14 days after the EPM retest session, 
showed the least number of DG neu-
rons/mm3 as well as the most number of 
dark neurons. In addition, sleep deprived 
animals especially in CPSR groups, showed 
to have a significant decline in their serum 
BDNF and a surge in their corticosterone 
levels. 
The use of elevated plus-maze (EPM) 
test-retest paradigm here, was an attempt to 
concomitantly assess the effects of such in-
terventions on anxiety, learning and 
memory (Asth et al., 2012). In terms of be-
havioral outcome of SD, in agreement with 
our findings, the majority of experimental 
studies have shown memory impairment 
and they report no effect or even indicate 
decreased anxiety in sleep-deprived rodents 
(Hicks and Moore, 1979; Moore et al., 
1979; Suchecki et al., 2002; Martinez-
Gonzalez et al., 2004; Tartar et al., 2009). 
However, there seem to be some inconsist-
encies in the literature, which may be the 
result of a complex interaction between the 
duration and the method of sleep depriva-
tion employed, the anxiety test involved, 
the differences in species and strains, and 
perhaps other variables and contributing 
factors. Apparently, explaining the relation-
ship between restricted or disrupted sleep 
and different types or stages of memory 
function and anxiety is not straight forward 
thus needs further investigations to become 
clearer. 
Many reports have suggested that sleep 
loss can decrease neurogenesis level by 
means of the changes occurred in stress sys-
tems. According to Mirescu et al. (2006), 
SD in rats hampers neurogenesis through a 
surge in the main stress hormone, corti-
costerone (Mirescu and Gould, 2006; 
Mirescu et al., 2006). Conversely, other 
studies have demonstrated that the neural 
damage due to SD is independent of corti-
costerone levels (Guzman-Marin et al., 
2007; Mueller et al., 2008). 
The adverse events seen following SD 
involve not only with changes in neuro-
transmitter systems and neuroinflammatory 
processes but also the cell signals regulat-
ing the neurogenesis and neurotrophic fac-
tors such as BDNF (Meerlo et al., 2009; 
Lucassen et al., 2010; Pathania et al., 2010). 
Earlier findings have reported that, the 
activity of the antioxidant enzyme superox-
ide dismutase (SOD) in the brainstem and 
hippocampus can be decreased by TSD and 
CPSR (Alzoubi et al., 2012). The multi-
functional proinflammatory cytokines such 
as TNFα and interleukin-1 beta (IL-1β), 
have not been only described as crucial in-
flammatory mediators, but also as factors 
crucial to the regulation of sleep mecha-
nisms (Krueger, 2008). Based on this, it is 
hypothesized that these conditions which 
activate the reactive oxygen species, can 
trigger a cascade of events which facilitate 
the release of proinflammatory factors such 
as TNFα and interleukins (IL1 and 6) in 
different brain areas including the hippo-
campal region. These are shown to attenu-
ate the secretion of BDNF which is a neu-
roprotective factor (Nagahara et al., 2009; 
Esumi et al., 2011; Alzoubi et al., 2012). 
The hippocampal BDNF is shown to criti-
cally contribute to synaptic plasticity, long-
term potentiation (LTP) and hence the 
memory function (Laske et al., 2007; 
Nagahara et al., 2009; Alhaider et al., 2011; 
Esumi et al., 2011; Havekes et al., 2012). 
According to the established positive corre-
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lation between the circulating BDNF level 
and its secretion in various brain regions 
(Angelucci et al., 2011), we measured the 
serum BDNF. Even if the cause for this 
positive correlation is not clearly known, 
our data may partly elucidate the contribu-
tion of the peripheral and central BDNF 
changes in possible brain insults following 
sleep deprivation. There are reports indicat-
ing that, after sleep deprivation, BDNF se-
cretion and therefore its concentration is 
diminished in areas of the brain including 
brain stem, hippocampus and cerebellum 
(Sei et al., 2000; Alhaider et al., 2011). This 
suggests that sleep plays a role in secretion 
of BDNF. Due to the BDNF contribution to 
learning and memory processes, sleep de-
privation is perceived to negatively affect 
the memory function. This is in line with 
what we found in our behavioral and neu-
robiochemical approach, as our results 
showed decreased BDNF post TSD and 
CPSR as compared to control conditions. 
Moreover, the SD-induced diminished level 
of BDNF was not seen in IFX-treated ani-
mals, suggesting the possible role of TNFα 
in the neuroinflammatory insults following 
SD. Nevertheless, the relationship between 
BDNF and SD-induced memory impair-
ment needs to be more deeply addressed in 
further studies.  
On the other hand, our results indicated 
an increased level of corticosterone in sleep 
deprived animals. Similar to our findings, 
some reports have indicated that the HPA 
axis activity occurs in sleep deprived ani-
mals although the level of such activation 
can in part result from the sleep deprivation 
method employed (Suchecki et al., 1998; 
Meerlo et al., 2002; Hipolide et al., 2005). 
The mechanism(s) mediating these ef-
fects of sleep restriction on HPA axis regu-
lation are yet to be fully explained and per-
haps involve the HPA axis itself, as well as 
its regulatory systems such as serotonergic 
inputs (Prevot et al., 1996; Gardner et al., 
1997; Lopez-Rodriguez et al., 2003; Hipo-
lide et al., 2005; Roman et al., 2005a, b; 
Meerlo et al., 2008). 
One of the brain regions which appears 
to be particularly sensitive and vulnerable 
to sleep loss is the hippocampus (Graves et 
al., 2003; McDermott et al., 2003; Ruskin et 
al., 2004). The hippocampus plays an im-
portant role in cognition and emotion regu-
lation (Bannerman et al., 2004; Bast, 2007) 
and is one of the few brain regions that dis-
plays consistency in neurogenesis from 
adolescence into adulthood (Ming and 
Song, 2005). The diminished hippocampal 
neurogenesis and its reduced volume have 
been implicated in the etiology and symp-
tomatology of depressive and emotional 
disorders (Sapolsky, 2000; Czeh and 
Lucassen, 2007; Perera et al., 2008; 
Boldrini et al., 2009; Lucassen et al., 2010). 
The question raised was whether sleep 
loss in long run may at least partly contrib-
ute to the neurodegenerative disorders such 
as Alzheimer’s Disease (AD) or hasten the 
process? To test this, we applied the IHC 
staining method for Aβ and HPτ in the hip-
pocampal DG. In presence of an apparent 
staining reaction for HPτ in PBO-treated 
CPSR rats with late brain excision com-
pared to other PBO- or IFX-treated animals, 
no Aβ deposition was noted across groups. 
One of the crucial pathways which 
might involve in neurodegeneration in 
sleep-restricted rats is the TNFα receptor 
system. Again, it remains to be established 
how TNFα turnover and receptor expres-
sion are affected following SD over a short 
or extended periods of time (D'Almeida et 
al., 1997; Gopalakrishnan et al., 2004; 
Lucassen et al., 2010). Some studies have 
shown that TNFα increases the oxidative 
stress measures following SD (D'Almeida 
et al., 1998; Ramanathan et al., 2002). In 
support of the latter notion, we showed that 
IFX (anti-TNFα MAb) at least partially 
prevents the behavioral, neurochemical and 
even histopathological consequences of SD.  
The negative effects of SD in rodents 
have been demonstrated with different 
methods of sleep deprivation (Guzman-
Marin et al., 2003, 2005, 2008; Mueller et 
al., 2008; Junek et al., 2010; Garcia-Garcia 
et al., 2011). Sleep disturbance for periods 
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shorter than 24 hours do not appear to af-
fect cell proliferation rates in GCL of the 
DG in rats’ hippocampus. Only few sleep 
deprivation studies showed the viability of 
all new cells. Results from one study indi-
cated that sleep loss reduces the survival of 
newly generated cells (Hairston et al., 
2005). Our findings were in line with the 
latter one, showing that chronic partial 
sleep restriction leads to the neuronal cell 
death in GCL of the DG. However, in con-
trast to our results, some investigations 
have reported no adverse effect of SD on 
cell survival in this region (Roman et al., 
2005a, b; Garcia-Garcia et al., 2011).  
Hippocampal cell death has similarly 
been reported in human sleep disorders 
such as primary insomnia (Riemann et al., 
2007) and sleep apnea (Morrell et al., 
2003). Among these lines, some researchers 
have observed reductions in the hippocam-
pal volume in psychopathologies such as 
major depression and subsequently reported 
these findings to be implicated in specific 
symptoms of such disorders (Sapolsky, 
2000; Czeh and Lucassen, 2007; Perera et 
al., 2008; Boldrini et al., 2009; Lucassen et 
al., 2010). 
Evidence suggesting a link between 
sleep loss and neurodegeneration comes 
from the diminished volume of the hippo-
campus and some other brain regions both 
in sleep-restricted humans and experimental 
animals (Sapolsky, 2000; Perera et al., 
2008; Boldrini et al., 2009; Altena et al., 
2010; Lucassen et al., 2010; Neylan et al., 
2010; Torelli et al., 2011; Bora et al., 2012). 
Studies which have demonstrated a reduced 
hippocampal volume following SD have 
brought about a variety of explanations 
such as neuronal cell death, shrinkage, di-
minished arborization in dendrites, slowed-
down/reduced neurogenesis, or decreases in 
the number of glial cells (Czeh and Lu-
cassen, 2007). 
The present findings which indicate cell 
loss in GCL of the hippocampal DG of rats, 
suggest that the hippocampal volume reduc-
tion observed in human sleep disorders and 
mood disorders may possibly be a conse-
quence of disrupted sleep rather than a non-
specific side-effect. This questionable no-
tion however needs to be investigated to be 
proven correct.  
With regard to our pharmacological in-
tervention, rats which received i.p. IFX, 15 
min before being submitted to the SD pro-
cedure, not only showed less memory im-
pairment compared to controls (PBO-
treated), but also comparatively preserved 
cell count in the GCL of their DG. This 
may further suggest the determinant role of 
TNFα in the possible neurodegenerative 
processes triggered by sleep loss. 
The effects of SD on BDNF in the pre-
sent study, supports the hypothesis that the 
reduction in neurogenesis and the corre-
sponding cell loss may have resulted from a 
reduction in such trophic factors or a possi-
ble dysregulation in their signaling. 
One way or another, sleep deprivation 
might constitute a threat to neuronal integri-
ty which however may not be sufficient to 
cause neurodegeneration but to activate 
neuroinflammatory mechanisms (Hsu et al., 
2003; Moldovan et al., 2010). 
In conclusion, the present study sug-
gests that the chronic SD results in a dam-
age caused by a neuroinflammatory insult. 
Other than the possible role of TNFα, fur-
ther mechanism(s) of this effect remain(s) 
to be established. Our findings support the 
hypothesis that insufficient sleep in long 
run sensitizes the brain to neurodegenera-
tive insults. This is possibly via activation 
of the inflammatory mechanisms in part 
through TNFα-associated pathways.  
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